# Description of Neurocognitive and Psychiatric Disorders Associated With Targeted Therapies Used in the Treatment of Lung Cancers With ALK/ROS1 Fusion and Their Impact on Patients' Quality of Life: Construction of an Experimental Patient-researcher Collaborative Care and Research Pathway

> **NCT06781905** · — · RECRUITING · sponsor: **Hospices Civils de Lyon** · enrollment: 20 (estimated)

## Conditions studied

- Metastatic Lung Cancer
- Metastatic Lung Cancer With ALK/ROS1 Fusion

## Interventions

- **OTHER:** Assessments of neuropsychiatric, neurocognitive and psychosocial alterations

## Key facts

- **NCT ID:** NCT06781905
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-16
- **Primary completion:** 2027-05-09
- **Final completion:** 2027-05-09
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06781905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06781905, "Description of Neurocognitive and Psychiatric Disorders Associated With Targeted Therapies Used in the Treatment of Lung Cancers With ALK/ROS1 Fusion and Their Impact on Patients' Quality of Life: Construction of an Experimental Patient-researcher Collaborative Care and Research Pathway". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06781905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*